NEW YORK -- (Business Wire)
Harwood Feffer LLP (www.hfesq.com)
is investigating potential claims against the board of directors of
Immucor, Inc. (“Immucor” or the “Company”) (NASDAQ: BLUD) concerning
possible breaches of fiduciary duty and other violations of law related
to the Company's agreement to be acquired by TPG Capital (“TPG”) in a
transaction valued at approximately $1.973 billion.
On July 5, 2011, Immucor announced that it had entered into a definitive
merger agreement under which the Company would be acquired by investment
funds managed by TPG pursuant to which Immucor shareholders will receive
$27.00 in cash for each share of Immucor they own. Our investigation
concerns possible breaches of fiduciary duty and other violations of law
related to the approval of the transaction by the Company's board of
directors; in particular, whether the Company undertook a fair process
to obtain fair consideration for all shareholders of Immucor. At least
one analyst has set a target price for the Company’s shares at $28.00
per share.
If you own shares of Immucor and would like to learn more about these
claims or if you wish to discuss these matters and have any questions
concerning this announcement or your rights, contact Daniella Quitt toll
free at (877) 935-7400 or to sign up online, visit www.hfesq.com.
You may also email Ms. Quitt at dquitt@hfesq.com.
For more information about class action cases in general, please visit
our website: www.hfesq.com.
Harwood Feffer LLP is a national shareholder litigation firm. Harwood
Feffer LLP is devoted to protecting the interests of individual and
institutional investors in shareholder actions in state and federal
courts nationwide.
Attorney Advertising. (C) 2011 Harwood Feffer LLP. The law firm
responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter.

Contacts:
Harwood Feffer LLP
Daniella Quitt, 877-935-7400
dquitt@hfesq.com
clowther@hfesq.com
Source: Harwood Feffer LLP
© 2026 Canjex Publishing Ltd. All rights reserved.